What happens next in GLP-1 — and when.

Get the briefing

What moved in the GLP‑1 field, in your inbox.

@glp1briefing

Indications › Obesity & overweight

GLP‑1 drugs in obesity & overweight

Which incretin agents are being studied in obesity & overweight, by whom, and when each trial is due to report. Conditions are grouped from the registry’s own wording, which records the same disease several ways.

Trials on file
423
Active
195
Results scheduled
97
Molecules studied
17
Sponsors
190

FDA-approved for obesity & overweight: liraglutide · orforglipron · semaglutide · tirzepatide. Approval wording is on each drug page, quoted from the label.

4 of the molecules tracked here are FDA-approved for obesity & overweight, so the trials below are asking further questions rather than establishing whether the class works at all. 308 of the 423 trials on file are phase 3 or later — the stage sized for a regulator to act on, against 115 still in early phases. 190 distinct sponsors are involved, 210 of the trials run commercially and the rest by universities and hospitals.

Molecules studied in this indication

VK2735 · aleniglipron · cagrilintide · danuglipron · dulaglutide · ecnoglutide · exenatide in this indication · liraglutide in this indication · maridebart cafraglutide in this indication · mazdutide in this indication · olatorepatide · orforglipron in this indication · petrelintide · retatrutide in this indication · semaglutide in this indication · survodutide · tirzepatide in this indication

Results due in this indication

Est. completionDrugTrialPhaseParticipants
2026-09-24mazdutideA Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
NCT06862908 · Innovent Biologics (Suzhou) Co. Ltd.
P2141
2026-10-15semaglutideMIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial
NCT07505303 · Eccogene
P2151
2026-11tirzepatideA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280 · Eli Lilly and Company
P3465
2026-11tirzepatideA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383 · Eli Lilly and Company
P3800
2026-11tirzepatideA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895 · Eli Lilly and Company
P3905
2026-11orforglipronA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · Eli Lilly and Company
P3600
2026-11-13olatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US
NCT07431086 · Regeneron Pharmaceuticals
P2120
2026-11-20semaglutideStudy to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
NCT06577090 · Skye Bioscience, Inc.
P2136
2026-11-30ecnoglutideA Study of Weekly Oral Dose of Ecnoglutide (VRB-101) for Weight Maintenance in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
NCT07553299 · Verdiva Bio Dev Limited
P2120
2026-12-01semaglutideA Study to Evaluate Tradipitant on Treating Nausea and Vomiting Induced by GLP-1R Agonist Use
NCT07446439 · Vanda Pharmaceuticals
P3280
2026-12-31semaglutideSit Less, Interact and Move More (SLIMM) 2 Study
NCT05173714 · Srinvasan Beddhu
P2156
2026-12-31semaglutideA Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
NCT06884293 · Innovent Biologics (Suzhou) Co. Ltd.
P3479
2026-12-31tirzepatideTIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
NCT06802081 · The Cleveland Clinic
P2100
2027-01-21maridebart cafraglutideEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839 · Amgen
P33,853
2027-02orforglipronA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
NCT06672549 · Eli Lilly and Company
P3125
2027-02-04tirzepatideEfficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
NCT07521631 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
P2372
2027-02-14tirzepatideEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT07481747 · Hudson Biotech
P32,539
2027-02-27semaglutideA Study to Compare XW003 Injection and Semaglutide Injection in Chinese Adults With Obesity (SLIMMER-UP-SWITCH)
NCT07073417 · Hangzhou Sciwind Biosciences Co., Ltd.
P2163
2027-03semaglutideA Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
NCT07101939 · Actimed Therapeutics Ltd
P2120
2027-03semaglutideA Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
NCT07285902 · Fujian Shengdi Pharmaceutical Co., Ltd.
P3572
2027-03-01semaglutideA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667 · Novo Nordisk A/S
P3609
2027-03-14retatrutideEffect of LY3437943 Versus Placebo in Participants Who Have Obesity or Are Overweight
NCT07467447 · Hudson Biotech
P2300
2027-03-20tirzepatideThe Effects of Tirzepatide in People With Overweight/Obesity and Coronary Artery Disease
NCT06606821 · Tina Vilsbøll
P4124
2027-04-27maridebart cafraglutideEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease
NCT06987695 · Amgen
P3279
2027-04-30semaglutideA Study of CS060380 Tablets in Patients With MASH and Obesity
NCT07466017 · Cascade Pharmaceuticals, Inc
P2130
2027-05tirzepatideSubcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
NCT06191848 · University of Melbourne
P4352
2027-05-07mazdutideA Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
NCT06931028 · Innovent Biologics (Suzhou) Co. Ltd.
P3260
2027-05-11cagrilintideWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
NCT07220642 · Novo Nordisk A/S
P3300
2027-05-12cagrilintideWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
NCT07220759 · Novo Nordisk A/S
P3330
2027-05-18semaglutideA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight
NCT07745504 · Novo Nordisk A/S
P3285
2027-05-31tirzepatideResistance Training to Prevent Muscle Loss During Treatment With Tirzepatide
NCT07777575 · Technical University of Munich
P4150
2027-06semaglutideTesting the Efficacy, Safety, and PK of 20E in Patients With Obesity Who Are Starting Treatment With the GLP-1 Agonist Semaglutide for Weight Loss.
NCT07411378 · Biophytis
P2164
2027-06-30semaglutidePhase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975 · Gan & Lee Pharmaceuticals.
P3420
2027-07-01semaglutideBariatric Surgery vs. Semaglutide vs. Tirzepatide
NCT06803888 · Ali Aminian
P4140
2027-07tirzepatideA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
NCT07438444 · Eli Lilly and Company
P4344
2027-07retatrutideA Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
NCT07232719 · Eli Lilly and Company
P3250
2027-07-01VK2735VK2735 for Weight Management Phase 3
NCT07104500 · Viking Therapeutics, Inc.
P34,500
2027-07-01VK2735VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383 · Viking Therapeutics, Inc.
P31,100
2027-07-12semaglutideA Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity
NCT07639021 · Novo Nordisk A/S
P2230
2027-08orforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472 · Eli Lilly and Company
P3600

Trials on file

All 423 incretin trials recorded in this indication, active first.

DrugTrialStatusPhaseParticipants
tirzepatideA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
NCT05556512 · Eli Lilly and Company
Active, not recruitingP315,374
maridebart cafraglutideEvaluating the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity
NCT07037433 · Amgen
RecruitingP312,800
maridebart cafraglutideMaridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
NCT07037459 · Amgen
RecruitingP35,056
VK2735VK2735 for Weight Management Phase 3
NCT07104500 · Viking Therapeutics, Inc.
Active, not recruitingP34,500
maridebart cafraglutideEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight
NCT06858839 · Amgen
Active, not recruitingP33,853
aleniglipronEfficacy and Safety of Aleniglipron in Participants With Obesity or Overweight With a Weight-Related Comorbidity (ACCOMPLISH-1)
NCT07654361 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RecruitingP33,600
semaglutideA Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
NCT05567796 · Novo Nordisk A/S
Active, not recruitingP33,400
maridebart cafraglutideExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)
NCT07684235 · Amgen
RecruitingP33,200
orforglipronA Study of Orforglipron (LY3502970) in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities
NCT05869903 · Eli Lilly and Company
Active, not recruitingP33,127
tirzepatideA Study of Tirzepatide (LY3298176) Compared With Standard of Care in Adult Participants With Obesity and Without Diabetes (SURMOUNT-REAL UK)
NCT07247084 · Eli Lilly and Company
RecruitingP43,000
tirzepatideEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1)
NCT07481747 · Hudson Biotech
RecruitingP32,539
semaglutideA Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight
NCT07564414 · Novo Nordisk A/S
RecruitingP32,500
orforglipronA Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity
NCT07794579 · Eli Lilly and Company
Not yet recruitingP32,001
tirzepatideA Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
NCT06143956 · Eli Lilly and Company
RecruitingP21,481
orforglipronA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
NCT06993792 · Eli Lilly and Company
Active, not recruitingP31,400
semaglutideEfficacy and Safety of Ribupatide Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
NCT07284979 · Kailera
RecruitingP31,200
VK2735VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)
NCT07104383 · Viking Therapeutics, Inc.
Active, not recruitingP31,100
aleniglipronA Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)
NCT07654374 · Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
RecruitingP31,100
semaglutideGLP-1 Plus Lifestyle for Overall Wellness: Find Your Way Forward
NCT06977438 · University of Minnesota
Not yet recruitingP41,020
semaglutideA Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation
NCT06299098 · Regeneron Pharmaceuticals
Active, not recruitingP21,005
semaglutideAMAZE 8: A Research Study Investigating How Well the Medicine NNC0487-0111 Compared to Semaglutide Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight
NCT07400107 · Novo Nordisk A/S
Not yet recruitingP31,000
maridebart cafraglutideExtension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-2-EXTENSION)
NCT07684144 · Amgen
RecruitingP3950
tirzepatideA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06914895 · Eli Lilly and Company
Active, not recruitingP3905
liraglutideLiraglutide Treatment in Obese Infertile PCOS Women
NCT06742710 · Peking University Third Hospital
RecruitingP4890
tirzepatideA Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity
NCT06662383 · Eli Lilly and Company
Active, not recruitingP3800
orforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
NCT06972459 · Eli Lilly and Company
Active, not recruitingP3800
tirzepatideEffect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients
NCT07715929 · Yunlong Wang
Not yet recruitingP4710
semaglutideA Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide
NCT07668414 · Novo Nordisk A/S
Not yet recruitingP3650
retatrutideA Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity
NCT06859268 · Eli Lilly and Company
Active, not recruitingP3643
semaglutideA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
NCT07011667 · Novo Nordisk A/S
Active, not recruitingP3609
orforglipronA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
NCT06972472 · Eli Lilly and Company
Active, not recruitingP3600
orforglipronA Master Protocol for Orforglipron in Participants With Obstructive Sleep Apnea and Obesity or Overweight
NCT06649045 · Eli Lilly and Company
Active, not recruitingP3600
retatrutideA Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight
NCT07357415 · Eli Lilly and Company
Active, not recruitingP3600
retatrutideA Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain
NCT07035093 · Eli Lilly and Company
Active, not recruitingP3586
semaglutideA Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity
NCT07285902 · Fujian Shengdi Pharmaceutical Co., Ltd.
Active, not recruitingP3572
semaglutideSTEP TEENS Weight Maintenance: A Research Study on How Well Semaglutide Helps Teenagers With Excess Body Weight to Lose Weight and Maintain Weight Loss
NCT06571383 · Novo Nordisk A/S
Active, not recruitingP4500
orforglipronA Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1
NCT06948435 · Eli Lilly and Company
Active, not recruitingP3487
petrelintideA Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight
NCT07589686 · Hoffmann-La Roche
Not yet recruitingP2486
semaglutideEfficacy and Safety of Semaglutide for Weight Loss in Overweight or Obese Adults in Bangladesh With or Without Type 2 Diabetes Mellitus
NCT06616961 · Popular Medical College Hospital
Not yet recruitingP3480
semaglutideA Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
NCT06884293 · Innovent Biologics (Suzhou) Co. Ltd.
Active, not recruitingP3479
tirzepatideA Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Obesity or Overweight
NCT06962280 · Eli Lilly and Company
Active, not recruitingP3465
semaglutideA Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
NCT07253285 · Novo Nordisk A/S
RecruitingP3460
semaglutideEfficacy and Safety of Semaglutide Injection Vs WEGOVY® in Chinese Obese Patients
NCT07036172 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RecruitingP3460
semaglutideResearch Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight
NCT07770841 · Novo Nordisk A/S
RecruitingP3450
tirzepatideEfficacy and Safety of Tirzepatide for Weight Management
NCT06918405 · Chittagong Medical College
Active, not recruitingP3440
semaglutidePhase III Clinical Study Comparing the Efficacy and Safety of GZR18 Injection and Semaglutide (Wegovy®) in Adult Obese or Overweight Subjects
NCT07150975 · Gan & Lee Pharmaceuticals.
RecruitingP3420
tirzepatideA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252 · Eli Lilly and Company
Active, not recruitingP2414
semaglutideA Clinical Study Comparing Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects
NCT06738979 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Not yet recruitingP3408
semaglutideA Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity
NCT06780449 · Novo Nordisk A/S
Active, not recruitingP3400
tirzepatideAI-assisted Multi-domain Lifestyle Versus Tirzepatide for Weight Loss Maintenance in Adults With Type 2 Diabetes (AIM-MAINTAIN)
NCT07555730 · Huazhong University of Science and Technology
Not yet recruitingP4400
tirzepatideEfficacy and Safety of HDM1005 Compared to Tirzepatide in Obese Adults Without Diabetes
NCT07521631 · Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
RecruitingP2372
semaglutideA Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
NCT06633783 · Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Not yet recruitingP3370
tirzepatideA Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes
NCT06603571 · Eli Lilly and Company
Active, not recruitingP2367
ecnoglutideA Study of Econoglutide Injection in Obese Participants With Knee Osteoarthritis (KOA)
NCT07734311 · Hangzhou Sciwind Biosciences Co., Ltd.
RecruitingP3360
olatorepatideStudy of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes
NCT07685808 · Regeneron Pharmaceuticals
RecruitingP2360
semaglutideBALANCE-OBS: Bofanglutide (GZR18) Versus Semaglutide in Latin American Adults With Overweight or Obesity
NCT07622810 · Carnot Laboratories
Not yet recruitingP3352
tirzepatideSubcutaneous Tirzepatide Once-weekly in Patients With Obesity and Knee Osteoarthritis (STOP KNEE-OA)
NCT06191848 · University of Melbourne
RecruitingP4352
tirzepatideMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
NCT06937086 · Eli Lilly and Company
RecruitingP3350
tirzepatideA Study of Tirzepatide (LY3298176) in Adult Participants in India With Either Type 2 Diabetes Mellitus or Obesity
NCT07438444 · Eli Lilly and Company
Active, not recruitingP4344
mazdutideEfficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
NCT07469800 · Innovent Biologics (Suzhou) Co. Ltd.
RecruitingP3336